Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.
about
Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens.Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma
P2860
Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Clinical Performance of CEA, C ...... ncer Using LOCI™-based Assays.
@en
Clinical Performance of CEA, C ...... ncer Using LOCI™-based Assays.
@nl
type
label
Clinical Performance of CEA, C ...... ncer Using LOCI™-based Assays.
@en
Clinical Performance of CEA, C ...... ncer Using LOCI™-based Assays.
@nl
prefLabel
Clinical Performance of CEA, C ...... ncer Using LOCI™-based Assays.
@en
Clinical Performance of CEA, C ...... ncer Using LOCI™-based Assays.
@nl
P2093
P356
P1433
P1476
Clinical Performance of CEA, C ...... ncer Using LOCI™-based Assays.
@en
P2093
Birgit Stoffel Wagner
Gisela Walgenbach-Brünagel
Jörg C Kalff
Ramona C Dolscheid-Pommerich
Stefan Holdenrieder
Steffen Manekeller
P304
P356
10.21873/ANTICANRES.11329
P407
P577
2017-01-01T00:00:00Z